The startup operates an oligonucleotide-based therapeutics platform that modulates RNA binding proteins to develop antibody-drug conjugates targeting solid tumors. This approach aims to provide effective treatment options for intractable diseases by leveraging RNA biology to enhance therapeutic efficacy.
Funding
Funding not disclosed
Founders
Product
Problem
Developing effective antibody-drug conjugates (ADCs) for solid tumors is challenging due to difficulties in achieving targeted drug delivery and overcoming drug resistance mechanisms. Traditional approaches often lack the specificity needed to minimize off-target effects and maximize therapeutic impact on tumor cells.
Solution
This startup is developing an oligonucleotide-based therapeutics platform designed to modulate RNA binding proteins (RBPs) and enhance the efficacy of ADCs in treating solid tumors. By targeting RBPs, the platform aims to precisely control RNA processing and translation, leading to increased expression of target proteins on tumor cells. This approach enhances ADC binding and internalization, resulting in more effective drug delivery and tumor cell killing. The platform seeks to overcome drug resistance by modulating RBP activity to sensitize tumor cells to the cytotoxic effects of the ADC payload.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions focused on developing novel cancer therapeutics, particularly ADCs for solid tumor indications.
Features
- Proprietary oligonucleotide library targeting a wide range of RNA binding proteins
- Rational design algorithms to optimize oligonucleotide sequences for RBP binding affinity and specificity
- High-throughput screening assays to identify lead oligonucleotide candidates that modulate target protein expression
- ADC conjugation chemistry optimized for stability, payload release, and minimal off-target effects
- In vivo models to evaluate ADC efficacy, tumor penetration, and safety profiles